摘要
目的探讨灯盏花素注射液对冠心病患者血清中高敏C反应蛋白(hs-CRP)和白介素-6(IL-6)水平的影响,并对其在冠心病治疗中的疗效进行分析。方法将43例冠心病患者随机分治疗组(22例)和对照组(21例),并以25名健康体检者作为正常组。对照组采用常规西医治疗,治疗组在对照组治疗基础上加用灯盏花素注射液40 mg加入生理盐水250 mL中静脉输注。检测并对比治疗组与对照组治疗前后血清hs-CRPI、L-6水平变化,分析其对冠心病的影响及作用,作出相关性分析,并分析了两组的疗效。结果治疗组和对照组治疗前血清hs-CRP和IL-6水平均明显高于正常组(P<0.01);治疗组治疗后3 d、7 d、15 d血清hs-CRP和IL-6水平较对照组明显下降(P<0.05或P<0.01),15 d时与正常组相比无统计学意义(P>0.05)。血清hs-CRP水平与IL-6水平呈明显的正相关(r=0.6 1 2 1,P<0.0 1)。在缓解心绞痛和心电图疗效方面,治疗组总有效率分别为9 0.9 1%和72.73%,均高于对照组85.71%和66.67%,两组比较差异有统计学意义(P<0.05)。结论 hs-CRP和IL-6共同参与了冠心病复杂的炎症反应,灯盏花素注射液对冠心病有确切疗效,并对冠心病心绞痛患者的疗效可能与降低冠心病患者的血清hs-CRP、IL-6水平有关。
Objective To explore the effect of breviscapine injection on levels of serum high sensitive C-reactive protein（hs-CRP）and interleukin-6（IL-6）in patients（pts） with coronary heart diseases（CHD）.Methods Forty-three pts with coronary heart diseases were divided into two groups：Treatment group（n=22） treated with breviscapine injection and conventional western medicine,and control group（n=21） treated with conventional western medicine.Twenty-five healthy subjects were as normal group.The levels of serum hs-CRP and IL-6 were tested.Results The levels of serum hs-CRP and IL-6 in control group and treatment group were higher than that in normal group（P〈0.01）.Compared with control group,the levels of serum hs-CRP and IL-6 in treatment group were reduced significantly after treatments at 3 d,7 d and 15 d（P〈0.05 or P〈0.01）,there was no difference with normal group（P〉0.05）at 15 d.The serum hs-CRP was correlated positively with IL-6 level（r=0.612 1,P〈0.01）.The relieve of angina pectoris and improvement of electrocardiogram in treatment group were 90.91% and 72.73%,respectively,and that in control group was 85.71% and 66.67%,respectively（P〈0.05）.Conclusion The breviscapine injection was effective for CHD,and it might be related to reduce the levels of serum hs-CRP and IL-6.
出处
《中西医结合心脑血管病杂志》
2011年第4期392-394,共3页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词
灯盏花素注射液
冠心病
高敏C反应蛋白
白介素-6
breviscapine injection
coronary heart diseases
high sensitive C-reactive protein
interleukin-6
